Advances in levodopa therapy for Parkinson disease

Dhall, Rohit; Kreitzman, David

doi:10.1212/wnl.0000000000002510

Cited by 52 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The younger age of onset, longer disease duration, higher levodopa dose, and longer duration of levodopa therapy are considered major clinical risk factors for LID (Zappia and Quattrone, 2008;Warren et al, 2013;Cilia et al, 2014;Perez-Lloret et al, 2017;Matarazzo et al, 2018;Picconi et al, 2018). Young PD patients had a higher risk of LID than PD patients with old age of onset (Kumar et al, 2005;Dhall and Kreitzman, 2016). We analyzed the effect of iron content of SN on all the above clinical risk factors and found that the QSM value of the whole SN showed high accuracy in discriminating PD with LID and HCs (whole SN, 0.9273; left SN, 0.9066; right SN, 0.91) and PD with LID and without LID (whole SN, 0.7163; left SN, 0.7059; right SN, 0.7024).…”

Section: Discussionmentioning

confidence: 99%

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease

Song

Mei

et al. 2021

Front. Neurosci.

View full text Add to dashboard Cite

ObjectiveTo investigate iron deposition in the substantia nigra (SN) of Parkinson’s disease (PD) patients associated with levodopa-induced dyskinesia (LID).MethodsSeventeen PD patients with LID, 17 PD patients without LID, and 16 healthy controls were recruited for this study. The mean QSM values of the whole, left, and right SN were compared among the three groups. A multivariate logistic regression model was constructed to determine the factors associated with increased risk of LID. The receiver operating characteristic curve of the QSM value of SN in discriminating PD with and without LID was evaluated.ResultsThe mean QSM values of the whole and right SN in the PD with LID were higher than those in the PD without LID (∗P = 0.03, ∗P = 0.03). Multivariate logistic regression analysis revealed that the QSM value of whole, left, or right SN was a predictor of the development of LID (∗P = 0.03, ∗P = 0.04, and ∗P = 0.04). The predictive accuracy of LID in adding the QSM value of the whole, left, and right SN to LID-related clinical risk factors was 70.6, 64.7, and 67.6%, respectively. The QSM cutoff values between PD with and without LID of the whole, left, and right SN were 148.3, 165.4, and 152.7 ppb, respectively.ConclusionThis study provides the evidence of higher iron deposition in the SN of PD patients with LID than those without LID, suggesting that the QSM value of the SN may be a potential early diagnostic neuroimaging biomarker for LID.

show abstract

Section: Discussionmentioning

confidence: 99%

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease

Song

Mei

et al. 2021

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Parkinson’s disease (PD) is a neurodegenerative disorder with progressive motor symptoms [1]. PD affects approximately 3% of the population over 65 years old [2] and is associated with a severe loss in function of dopaminergic neurons within the substantia nigra pars compacta [3].…”

Section: Introductionmentioning

confidence: 99%

“…Since the discovery that dopamine loss is associated with PD, this medication is recognized as the most effective drug for PD treatment [1, 21]. However, long-term use of the medication leads to a levodopa-induced decrease in the efficacy of motor benefits and an increase in the incidence of adverse effects, which can contribute to worsening quality of life [20, 22, 23].…”

Section: Introductionmentioning

confidence: 99%

Feature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments

et al. 2016

View full text Add to dashboard Cite

BackgroundOver the years, a number of distinct treatments have been adopted for the management of the motor symptoms of Parkinson’s disease (PD), including pharmacologic therapies and deep brain stimulation (DBS). Efficacy is most often evaluated by subjective assessments, which are prone to error and dependent on the experience of the examiner. Our goal was to identify an objective means of assessing response to therapy.MethodsIn this study, we employed objective analyses in order to visualize and identify differences between three groups: healthy control (N = 10), subjects with PD treated with DBS (N = 12), and subjects with PD treated with levodopa (N = 16). Subjects were assessed during execution of three dynamic tasks (finger taps, finger to nose, supination and pronation) and a static task (extended arm with no active movement). Measurements were acquired with two pairs of inertial and electromyographic sensors. Feature extraction was applied to estimate the relevant information from the data after which the high-dimensional feature space was reduced to a two-dimensional space using the nonlinear Sammon’s map. Non-parametric analysis of variance was employed for the verification of relevant statistical differences among the groups (p < 0.05). In addition, K-fold cross-validation for discriminant analysis based on Gaussian Finite Mixture Modeling was employed for data classification.ResultsThe results showed visual and statistical differences for all groups and conditions (i.e., static and dynamic tasks). The employed methods were successful for the discrimination of the groups. Classification accuracy was 81 ± 6% (mean ± standard deviation) and 71 ± 8%, for training and test groups respectively.ConclusionsThis research showed the discrimination between healthy and diseased groups conditions. The methods were also able to discriminate individuals with PD treated with DBS and levodopa. These methods enable objective characterization and visualization of features extracted from inertial and electromyographic sensors for different groups.

show abstract

“…[23,24,25] These include elevations in liver and kidney function test parameters, such as alkaline phosphatase, serum glutamic-oxaloacetic transaminase/aspartate aminotransferase, serum glutamic-pyruvic transaminase/alanine aminotransferase, and bilirubin levels, and abnormalities in BUN and creatinine levels. [23] Thrombocytopenia has also been reported. Nevertheless, in our study, no abnormality in laboratory data was detected.…”

Section: Discussionmentioning

confidence: 99%

Levodopa Plus Occlusion Therapy versus Occlusion Therapy Alone for Children with Anisometropic Amblyopia

Farvardin

Khalili

Behnia

2019

JOVR

View full text Add to dashboard Cite

Purpose This study aimed to compare the effects of short-term administration of levodopa plus occlusion therapy versus occlusion therapy alone in preschool children with hyperopic anisometropic amblyopia.Methods This comparative interventional study included 40 eligible preschool children aged 6 to 7 years with hyperopic anisometropic amblyopia. The primary outcome measure was the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity recorded at baseline, 3 weeks after the treatment initiation and 12 weeks after the treatment termination. The results were compared between the two groups.ResultsNo statistically significant intergroup difference was observed in baseline logMAR visual acuities (P = 0.92). The mean logMAR visual acuities of the amblyopic eyes were significantly better in both groups three weeks after the treatment initiation than the baseline (P < 0.01 in both groups). At 12 weeks after treatment termination, the logMAR visual acuities of the amblyopic eyes were significantly better than the baseline values (P < 0.001 in the placebo group and P = 0.09 in the levodopa group). Intergroup comparisons revealed no statistically significant difference in visual acuities 3 weeks after the treatment initiation (P = 0.11) and 12 weeks after the treatment termination (P=0.10). Twelve weeks after the treatment termination, visual acuities regressed 0.037 logMAR in the placebo group and 0.042 logMAR in the levodopa group. These regression rates were not significantly different (P = 0.89).ConclusionThe results of this study provide evidence that adding short-term administration of levodopa to occlusion therapy in hyperopic anisometropic amblyopia offers no additional benefit in visual outcomes and provides no advantage in terms of the regression rate.

show abstract

Advances in levodopa therapy for Parkinson disease

Cited by 52 publications

References 47 publications

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease

Feature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments

Levodopa Plus Occlusion Therapy versus Occlusion Therapy Alone for Children with Anisometropic Amblyopia

Contact Info

Product

Resources

About